Navidea Biopharma (NAVB) Misses Q3 EPS by 1c

Navidea Biopharma (NYSE: NAVB) reported Q3 EPS of ($0.05), $0.01 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $3.98 million versus the consensus estimate of $2.78 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results
• MIND Technology (MIND) Misses Q1 EPS by 5c